VOY Advises 415 Capital on Investment in TRiCares
A VOY team led by André Buchholtz advised MedTech venture capital fund 415 Capital on its new investment in TRiCares. 415 Capital was the lead investor of the EUR 47M Series C financing round.
The financing round was completed by renowned existing investors, including Andera Partners, Wellington Partners Life Sciences, BioMedPartners, Crédit Mutuel Innovation, GO CAPITAL, and Karista.
About 415 Capital
415 Capital is a specialist venture capital firm that partners with exceptional entrepreneurs to bring breakthrough medical technologies to patients. In addition to early- and development-stage capital, 415 Capital leverages relationships with over 200 clinical sites and dozens of thought leaders to build value for its portfolio companies.
Over the years, the 415 Capital team has introduced over 25 breakthrough technologies to market and realized over 20 successful portfolio exits to date, including Vesper Medical and Intact Vascular (both acquired by Philips), Claret Medical (acquired by Boston Scientific), ReCor Medical (acquired by Otsuka), CardiAQ Valve Technologies (acquired by Edwards), Atritech (acquired by Boston Scientific), CoreValve (acquired by Medtronic) and many more.
About TRiCares
TRiCares is a pioneer in the minimally invasive treatment of tricuspid regurgitation, a devastating condition that affects millions of patients worldwide.
About VOY
VOY is a law firm and tax consultancy for founders and investors creating a digital client experience that focuses on additional value with direct and uncomplicated legal advice of the highest quality.
